| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | Boo; Diva; BCL-B; bcl2-L-10 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human BCL2L10 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于BCL2L10抗体的参考文献(摘要内容为简化概括)：
1. **文献名称**: "BCL2L10/Boo is a novel regulator of apoptosis in breast cancer cells"
**作者**: Lee EF, et al.
**摘要**: 研究利用特异性BCL2L10抗体揭示其在乳腺癌细胞中通过调控线粒体膜电位抑制凋亡的机制，并发现其高表达与化疗耐药相关。
2. **文献名称**: "Development of a monoclonal antibody against BCL2L10 for immunohistochemical analysis in ovarian cancer"
**作者**: Zhang Y, et al.
**摘要**: 报道了一种新型BCL2L10单克隆抗体的开发，验证其在卵巢癌组织中的特异性表达，发现其表达水平与患者预后显著相关。
3. **文献名称**: "BCL2L10 interacts with pro-apoptotic proteins to modulate TRAIL-induced apoptosis in colorectal carcinoma"
**作者**: Chen L, et al.
**摘要**: 通过BCL2L10抗体进行免疫共沉淀实验，证明其与Bax/Bak蛋白互作，抑制TRAIL通路诱导的结直肠癌细胞凋亡，提示其作为治疗靶点的潜力。
*注：以上文献为虚拟示例，实际引用需查询PubMed等数据库获取真实研究。*
×
